Posted by Michael Wonder on 07 Jan 2021
Merus granted FDA fast track designation of zenocutuzumab for the treatment of patients with neuregulin 1 fusion cancers
7 January 2021 - NRG1 fusions are rare mutations in many types of solid tumours, including non-small cell lung cancer and pancreatic cancer.
Merus today announced that the U.S. FDA has granted fast track designation to zenocutuzumab for the treatment of patients with metastatic solid tumours harbouring NRG1 gene fusions (NRG1+ cancers) that have progressed on standard of care therapy.
